Evidence map›Paper›PMID 39706878›Full record

ArticleBone marrow transplantation2025

Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.

Fangfang Yu, Jiahua Niu, Jianmin Yang, Jian Hou, Siguo Hao, Aibin Liang, Hong Xiong, Qi Zhu, Ligen Liu, Jun Shi and 8 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Fangfang Yu *Department of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, China.
Jiahua Niu *Department of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, China.
Jianmin YangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Jian HouDepartment of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, China.
Siguo HaoDepartment of Hematology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China.
Aibin LiangDepartment of Hematology, Tongji Hospital of Tongji University, Shanghai, 200065, China.ORCID 0000-0002-8978-1987
Hong XiongDepartment of Hematology, Xuhui Hospital, Fudan University, Shanghai, 200031, China.
Qi ZhuDepartment of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Ligen LiuDepartment of Hematology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200336, China.
Jun ShiDepartment of Hematology, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Juan DuDepartment of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, 200003, Shanghai, China.ORCID 0000-0003-2538-4007
Bobin ChenDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Rong WeiDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Wenli ZhaoDepartment of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai Fengxian District Central Hospital, Shanghai, 201499, China.
Lihua SunDepartment of Hematology, Zhongshan Hospital Qingpu Branch, Fudan University, Shanghai, 201700, China.
Yunhua HouDepartment of Hematology and Oncology, Minhang Hospital, Fudan University, Shanghai, 201199, China.
Rong TaoDepartment of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. rtao@shca.org.cn.ORCID 0000-0001-5766-1625
Xianmin SongDepartment of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, China. shongxm@sjtu.edu.cn.ORCID 0000-0003-0637-5324

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81570148
6 · The paper itself

Abstract

In this real-world study, 153 adult T-cell lymphoblastic lymphoma (T-LBL) patients from sixteen centers in Shanghai were enrolled. Out of them, 103 (67.3%) achieved complete remission (CR). The 2-year overall survival (OS) and progression-free survival (PFS) were 56.3% and 47.6%, respectively. In multivariate analysis, CR after induction treatment significantly improved the OS (p = 0.002) and PFS (p = 0.001). Among CR patients, allogeneic peripheral blood stem cell transplantation (allo-PBSCT) significantly lowered the cumulative incidence of relapse (CIR) compared to autologous PBSCT (p = 0.043) and non-SCT (p = 0.001). Among patients undergoing allo-PBSCT in CR, early (within four induction courses) and late CR (after four induction courses) didn't impact the prognosis with similar 2-year OS (p = 0.590), PFS (p = 0.858), CIR (p = 0.50), and non-relapse mortality (NRM) (p = 0.110). Early and deferred allo-PBSCT for early CR patients also yielded similar 2-year OS (p = 0.640), PFS (p = 0.970), CIR (p = 0.994), and NRM (p = 0.974). As a time-dependent covariate, allo-PBSCT presented a positive effect on PFS (p = 0.018) and had a trend toward better OS (p = 0.064). These data suggested that allo-PBSCT should be considered for T-LBL patients upon achieving CR to enhance survival and reduce relapse risk.

Indexed as

Peripheral Blood Stem Cell TransplantationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultAgedChinaFemaleHumansMaleMiddle AgedSurvival RateTransplantation, HomologousYoung Adult

Identifiers

PMID39706878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.